NRA-LACOSAMIDE 150 MG — DIN 02499584
LACOSAMIDE : 150 MG · NORA PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is NRA-LACOSAMIDE?
NRA-LACOSAMIDE 150 MG contains LACOSAMIDE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02499584, held by NORA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Aug-2023. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NRA-LACOSAMIDE used for?
NRA-LACOSAMIDE (lacosamide) is indicated as monotherapy in the management of partial-onset seizures in adult patients with epilepsy, and as adjunctive therapy in the management of partial-onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lacosamide cost around the world?
Lacosamide is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 7 | 141 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 32 | 81 | EUR███.██ |
| United States | acquisition | 7 | 77 | USD███.██ |
| Saudi Arabia | public | 20 | 47 | SAR███.██ |
| Czechia | max producer price (ex-factory) | 8 | 45 | CZK███.██ |
| Greece | producer price (ex-factory) | 31 | 31 | EUR███.██ |
| Bahrain | retail (max) | 4 | 19 | BHD███.██ |
| Hungary | producer price (ex-factory) | 15 | 19 | HUF███.██ |
| Austria | KVP (Kassenverkaufspreis) | 10 | 16 | EUR███.██ |
| United Arab Emirates | public | 13 | 13 | AED███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Luxembourg | reimbursement | 5 | 5 | EUR███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
505 pack listings across 163 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Lacosamide pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Lacosamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
16 holders have a Canadian DIN containing Lacosamide, across 66 DINs, of which 41 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| UCB CANADA INC | 5 | 5 | VIMPAT | Sourceable in Canada |
| PHARMASCIENCE INC | 8 | 4 | PHARMA-LACOSAMIDE, PMS-LACOSAMIDE | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 4 | 4 | ACH-LACOSAMIDE | Sourceable in Canada |
| AURO PHARMA INC | 4 | 4 | AURO-LACOSAMIDE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 4 | 4 | JAMP-LACOSAMIDE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 4 | 4 | MAR-LACOSAMIDE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 4 | 4 | MINT-LACOSAMIDE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 4 | SANDOZ LACOSAMIDE | Sourceable in Canada |
| SANIS HEALTH INC | 4 | 4 | LACOSAMIDE | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 4 | TEVA-LACOSAMIDE | Sourceable in Canada |
| ALEMBIC PHARMACEUTICALS LIMITED | 4 | 0 | ALEMBIC-LACOSAMIDE | No marketed DIN |
| APOTEX INC | 4 | 0 | APO-LACOSAMIDE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lacosamide |
|---|---|
| ATC code | N03AX18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02499584 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2499584 |
| Brand name | NRA-LACOSAMIDE |
| Generic / active ingredient | LACOSAMIDE : 150 MG |
| Market authorization holder | NORA PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | N03AX18 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AX |
| Current status | CANCELLED POST MARKET |
| Status date | 17-Aug-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
41 of 66 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-LACOSAMIDE | 50 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02489287 |
| ACH-LACOSAMIDE | 150 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02489309 |
| ACH-LACOSAMIDE | 200 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02489317 |
| ACH-LACOSAMIDE | 100 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02489295 |
| AURO-LACOSAMIDE | 50 MG | TABLET | AURO PHARMA INC | MARKETED | 02475332 |
| AURO-LACOSAMIDE | 150 MG | TABLET | AURO PHARMA INC | MARKETED | 02475359 |
| AURO-LACOSAMIDE | 200 MG | TABLET | AURO PHARMA INC | MARKETED | 02475367 |
| AURO-LACOSAMIDE | 100 MG | TABLET | AURO PHARMA INC | MARKETED | 02475340 |
| JAMP-LACOSAMIDE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02488388 |
| JAMP-LACOSAMIDE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02488418 |
2 · Same class — other molecules in ATC N03AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levetiracetam | ABBOTT-LEVETIRACETAM · ACH-LEVETIRACETAM · AG-LEVETIRACETAM · APO-LEVETIRACETAM · +31 more | 109 | 47 | Yes |
| Topiramate | ABBOTT-TOPIRAMATE · ACCEL-TOPIRAMATE · ACH-TOPIRAMATE · AG-TOPIRAMATE · +32 more | 125 | 42 | Yes |
| Lacosamide | ACH-LACOSAMIDE · AG-LACOSAMIDE · ALEMBIC-LACOSAMIDE · APO-LACOSAMIDE · +12 more | 66 | 41 | Yes |
| Lamotrigine | AG-LAMOTRIGINE · APO-LAMOTRIGINE · AURO-LAMOTRIGINE · DOM-LAMOTRIGINE · +13 more | 48 | 29 | Yes |
| Brivaracetam | APO-BRIVARACETAM · AURO-BRIVARACETAM · BRIVLERA | 14 | 14 | Yes |
| Perampanel | FYCOMPA · TARO-PERAMPANEL | 13 | 12 | Yes |
| Cenobamate | XCOPRI | 11 | 8 | Yes |
| Stiripentol | DIACOMIT | 4 | 3 | Yes |
| Cannabidiol | EPIDIOLEX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AF | Carbamazepine · Eslicarbazepine · Oxcarbazepine · Rufinamide | 86 | 33 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NRA-LACOSAMIDE called?
The same molecule, Lacosamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Vimpat | Latin | Australia, Bahrain, Czechia, Saudi Arabia |
| LACOMED | Latin | Australia |
| Vimcosa | Latin | Australia |
| Lacosamide Sandoz | Latin | Australia |
| Lacosam | Latin | Australia |
| Lacosamide ARX | Latin | Australia |
| Lacosamide Lupin | Latin | Australia |
| ARKVIMMA | Latin | Czechia |
| Lusam | Latin | Bahrain, Saudi Arabia |
| Trepadio | Latin | Bahrain, Saudi Arabia |
| TRELEMA | Latin | Czechia |
| KANILAD | Latin | Czechia |
| LACOSAMIDE ACCORD | Latin | Czechia |
| LACOSAMIDE ALH | Latin | Saudi Arabia |
| LACOSAMIDE GENEPHARM | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.